论文部分内容阅读
目的 研究外周血中ｓＩＬ－ ２Ｒ、ＩＬ－ ６ 和淋巴细胞亚群鉴别良、恶性卵巢肿瘤的临床意义。方法 应用ＥＬＩＳＳＡ法、间接免疫荧光法测定５９ 例卵巢肿瘤患者外周血ｓＩＬ－２Ｒ、ＩＬ－ ６ 和Ｔ淋巴细胞亚群。结果 ①２１ 例卵巢恶性肿瘤患者入院时，ｓＩＬ－２ 高达３３７．５ ±１５８ ．１３ｐｇ／ｍｌ，显著高于对照组及卵巢良性肿瘤组（ Ｐ＜ ０．００１）。ＩＬ－６ 浓度变化主要见于卵巢癌患者（ Ｐ＜ ０．０１），并与临床预后相关。②所有患者外周血ＣＤ３＋ 和ＣＤ８＋ 无明显改变，卵巢恶性肿瘤中２１ 例有１７ 例ＣＤ４＋ 细胞显著减少，ＣＤ４＋／ＣＤ８＋ 显著低于对照组及良性卵巢肿瘤组（ Ｐ＜ ０ ．０１）。③卵巢癌外周血ＣＤ１６ 和ＣＤ５６ 的表达均显著高于对照组（Ｐ＜ ０．０１） 。结论 测定外周血ｓＩＬ－２Ｒ、ＩＬ－６ 浓度，联合Ｔ 淋巴细胞亚群分析，可作为鉴别良、恶性卵巢肿瘤的指标，对恶性卵巢肿瘤还具有判断预后作用。
Objective To study the clinical significance of sIL-2R, IL-6 and lymphocyte subsets in peripheral blood to identify benign and malignant ovarian tumors. Methods ELISSA method and indirect immunofluorescence assay were used to determine the subgroups of sIL-2R, IL-6 and T lymphocyte in peripheral blood of 59 patients with ovarian cancer. Results ①21 cases of ovarian cancer patients admitted to hospital, sIL-2 up to 337.5 ± 158. 13pg / ml, significantly higher than the control group and benign ovarian tumor group (P <0.001). The change of IL-6 concentration mainly found in ovarian cancer patients (P <0.01), and with the clinical prognosis. ② There was no significant change in peripheral blood CD3 + and CD8 + in all patients. In 21 cases of ovarian malignant tumors, 17 cases of CD4 + cells were significantly decreased and CD4 + / CD8 + was significantly lower than that of control group and benign ovarian tumor group (P <0.01). ③ The expression of CD16 and CD56 in peripheral blood of patients with ovarian cancer were significantly higher than that of the control group (P <0.01). Conclusion The determination of peripheral blood sIL-2R and IL-6 levels in combination with T-lymphocyte subsets analysis can be used as an index to differentiate benign and malignant ovarian tumors, and has a prognostic value for malignant ovarian tumors.